Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

Crivit Apr. 3 at 11:51 AM

$IMUX https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=319930860&type=PDF&symbol=IMUX&cdn=eec3453f41a5b8a9d463704ed486749a&companyName=Immunic+Inc.&formType=S-3&dateFiled=2026-04-02

2 · Reply

Mattjen Apr. 3 at 12:54 AM

$IMUX we're going to have a fun ride to topline.

1 · Reply

Mattjen Apr. 3 at 12:51 AM

$IMUX S3 has been filed, as expected.

0 · Reply

Marcelkluetz Apr. 2 at 2:06 PM

$IMUX Anyone else on here surprised that compliance was regained after 20 days when we all thought it was 10 days...? Either way, onward and up!

1 · Reply

ErnieWorthing84 Apr. 2 at 1:58 PM

$IMUX https://open.spotify.com/episode/34JlFsEVHaBjELhE02cHfk?si=LxYZdNnrR_mSmAyzlgqW_Q&nd=1&dlsi=fd4bf9b2eabc440a

0 · Reply

Teddy313 Apr. 1 at 5:12 PM

$IMUX Who cares RS no RS everything is going in the right direction tons of money drugs moving alone compliance finished. All we have to do is be patient and wait for the big payoff. I’m loaded and holding as long as i have to.

2 · Reply

Jw242 Apr. 1 at 3:13 PM

$IMUX hate to be a broken record but the RS is 98.5% guaranteed and forced by the PIPE buyers. = who cares and would actually benefit us long term

2 · Reply

ccledez Apr. 1 at 1:52 PM

$IMUX really good play but that RS overhang is frustrating the stock in my opinion. Sigh

4 · Reply

Jw242 Apr. 1 at 1:21 PM

$IMUX compliant 🤷

0 · Reply

StocktwitsNews Apr. 1 at 10:59 AM

IMUX Stock Jumps 6% Pre-Market Today – Here’s The Latest Update On Its Compliance With Nasdaq Listing Rules $IMUX https://stocktwits.com/news/equity/markets/why-did-imux-stock-gain-in-pre-market-today/cZ7HS4ARInF

0 · Reply

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 31, 2026, 6:30 AM EDT - 5 days ago

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Mar 10, 2026, 6:30 AM EDT - 26 days ago

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Mar 3, 2026, 6:30 AM EST - 4 weeks ago

Immunic to Participate in Investor Conferences in March

Feb 26, 2026, 6:30 AM EST - 5 weeks ago

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Feb 17, 2026, 4:05 PM EST - 6 weeks ago

Immunic Announces Closing of Oversubscribed Private Placement Financing

Feb 13, 2026, 11:25 AM EST - 7 weeks ago

Immunic Stock Jumps After Pricing $400 Million Private Placement

Feb 13, 2026, 6:30 AM EST - 7 weeks ago

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Feb 4, 2026, 6:30 AM EST - 2 months ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Jan 7, 2026, 6:30 AM EST - 3 months ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Nov 26, 2025, 6:30 AM EST - 4 months ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 13, 2025, 6:30 AM EST - 5 months ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:30 AM EDT - 5 months ago

Immunic to Participate in Industry and Investor Conferences in November

Oct 1, 2025, 6:30 AM EDT - 6 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Sep 25, 2025, 6:30 AM EDT - 6 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 7 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 4, 2025, 6:30 AM EDT - 7 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Aug 7, 2025, 6:30 AM EDT - 8 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 24, 2025, 6:30 AM EDT - 10 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 9, 2025, 5:51 PM EDT - 10 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 5, 2025, 6:30 AM EDT - 10 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 10 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 10 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 11 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 11 months ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 1 year ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 28, 2025, 2:09 AM EDT - 1 year ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 10, 2025, 1:00 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 3, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 1 year ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 4, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 9, 2024, 8:37 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Crivit Apr. 3 at 11:51 AM

2 · Reply

Mattjen Apr. 3 at 12:54 AM

$IMUX we're going to have a fun ride to topline.

1 · Reply

Mattjen Apr. 3 at 12:51 AM

$IMUX S3 has been filed, as expected.

0 · Reply

Marcelkluetz Apr. 2 at 2:06 PM

$IMUX Anyone else on here surprised that compliance was regained after 20 days when we all thought it was 10 days...? Either way, onward and up!

1 · Reply

ErnieWorthing84 Apr. 2 at 1:58 PM

$IMUX https://open.spotify.com/episode/34JlFsEVHaBjELhE02cHfk?si=LxYZdNnrR_mSmAyzlgqW_Q&nd=1&dlsi=fd4bf9b2eabc440a

0 · Reply

Teddy313 Apr. 1 at 5:12 PM

2 · Reply

Jw242 Apr. 1 at 3:13 PM

$IMUX hate to be a broken record but the RS is 98.5% guaranteed and forced by the PIPE buyers. = who cares and would actually benefit us long term

2 · Reply

ccledez Apr. 1 at 1:52 PM

$IMUX really good play but that RS overhang is frustrating the stock in my opinion. Sigh

4 · Reply

Jw242 Apr. 1 at 1:21 PM

$IMUX compliant 🤷

0 · Reply

StocktwitsNews Apr. 1 at 10:59 AM

0 · Reply

DARKP00L Apr. 1 at 10:54 AM

$IMUX 06:31 on Apr. 01 2026 Immunic Regains Nasdaq Compliance #tradeideas

0 · Reply

DARKP00L Apr. 1 at 10:45 AM

$IMUX 06:31 on Apr. 01 2026 Immunic Regains Nasdaq Compliance #tradeideas

0 · Reply

SmokeyR1949 Apr. 1 at 1:37 AM

$IMUX "StockInvest" shows for Tue. Mar.31st. Close an RSI:14=34 the stock Lies in the Lower Part of a Very Wide & Strong Rising Trend and is Expected to Rise 88% in the next 3 Mos. with a 90% Chance of a Low of $1.97 and a High of $3.07 Insiders Sentiment is strong fueled by Insiders Open Market Buying !! And is Rated a "Buy" !! p.s. always do your own "DD" and always Fact Check !!

0 · Reply

dgbio Mar. 31 at 5:11 PM

$IMUX Congleton is a good addition and he could be free and rich soon

0 · Reply

coujatrader Mar. 31 at 4:47 PM

$IMUX what does she want to do hmmm

0 · Reply

ErnieWorthing84 Mar. 31 at 4:45 PM

$IMUX XBI so hard right now

0 · Reply

Jw242 Mar. 31 at 3:26 PM

$IMUX “kinda” trusted Vittardio but more for the science Hopefully the CongleTardio new team member can get us to the Final Four!

2 · Reply

Mattjen Mar. 31 at 2:58 PM

$IMUX 500k in stock options vested over 3 years.... thats interesting.

0 · Reply

Mvvh1987 Mar. 31 at 10:55 AM

$IMUX appoints Jon Congleton to the board — nearly 40 years biopharma experience and part of the original Copaxone US launch team. This is serious MS commercial expertise added ahead of pivotal Phase 3 readouts. You don’t bring in a Copaxone veteran unless you’re preparing for real value creation post‑data.

3 · Reply

Jw242 Mar. 31 at 10:54 AM

$IMUX our new savior? 🤞

0 · Reply

Jw242 Mar. 31 at 10:39 AM

$IMUX let’s do the Congleton shuffle Nice hire as CEO. Good history he has

0 · Reply

texmade2 Mar. 30 at 8:23 PM

$SLS $IBRX $IMUX $GEVO Trump: I’ll obliterate Iran and walk away from Strait of Hormuz Get ready for Taco Tuesday

1 · Reply

Market Cap	151.34M
Revenue (ttm)	0.00
Net Income (ttm)	-97.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	808,600
Avg Vol	3,927,654
Day's Range	N/A - N/A
Shares Out	130.47M
Stochastic %K	41%
Beta	1.37
Analysts	Strong Sell
Price Target	$5.00